After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help…
Collaboration will develop and market Satellite Hot Labs for radiolabeling of BioGuides
BeCAT - The therapy of the future is developed here
At Charité's "Berlin Center for Advanced Therapies" (BeCAT), the new class of Advanced Therapy Medicinal Products (ATMP) has been under development since 2018. In 2024, it will move into the new…
The patient population that benefits most from treatment with enibarcimab in septic shock can be clearly defined by two biomarkers, according to data presented today
In the AdrenOSS-2 study, the relevant subgroup had a significant reduction in…
PRAMOMOLECULAR GmbH, a spin-off of the Technische Universität Berlin, uses gene silencing to down-regulate cancer proteins and thus reduce tumor growth. This makes it possible to address cancers in a well-tolerated and targeted manner that cannot be…
Two researchers, one from Charité – Universitätsmedizin Berlin and one from the Berlin Institute of Health at Charité (BIH), have been selected for grants by the European Research Council for their ideas. Dr. Birgit Nemec holds the position of…
Another center for cutting-edge research in medicine is being built in Berlin. The new building, called "Der Simulierte Mensch" (Si-M), will provide space for around 140 researchers from science and clinical practice to carry out their scientific…
There is growing evidence that peptide hormones from the gut have far-reaching effects on the whole organism. By binding to corresponding receptors in the brain, they can modulate food intake and alter metabolic parameters. However, the role of these…
Bartter syndrome type 3 is the result of several structural variants in the genome. By using long-read sequencing, Janine Altmüller and her team from the Max Delbrück Center, the Berlin Institute of Health at Charité (BIH) and University Hospital…
Reykjavik, Iceland and Berlin, Aug. 18, 2023 — Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging…
